| Biotechnology Industry | Healthcare Sector | Richard Hague CEO | NASDAQ (NGS) Exchange | 731094207 CUSIP |
| US Country | 42 Employees | - Last Dividend | 17 May 2022 Last Split | - IPO Date |
RegenETP, Inc. is a clinical-stage biotechnology company specializing in the development and commercialization of innovative regenerative tissue products and biomaterials. Operating primarily in the United States, the company serves the fields of medicine, biomedical engineering, and material sciences. RegenETP is structured into two main segments: Regenerative Medicine Products and Contract Services. Through its pioneering efforts, the company aims to enhance patient outcomes in various medical applications, particularly focusing on skin repair and regeneration.
Previously known as PolarityTE, Inc., the company rebranded to RegenETP, Inc. in August 2023, reflecting its commitment to advancing therapeutic solutions. Headquartered in Salt Lake City, Utah, RegenETP is dedicated to developing cutting-edge technologies that address critical medical needs.
SkinTE is a regenerative tissue product specifically designed for the repair, reconstruction, replacement, and supplementation of skin. It is utilized in various medical scenarios, including the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. SkinTE aims to provide effective solutions for skin-related challenges faced by patients.
SkinTE Cryo is a state-of-the-art product allowing multiple deployments from a single original harvest thanks to a cryopreservation process. This innovative approach ensures the preservation of the tissue while maintaining its viability for subsequent uses, enhancing the flexibility and effectiveness of skin regeneration treatments.
This point-of-care device facilitates the immediate processing and deployment of SkinTE right after the initial harvest. By enabling on-site preparation, it significantly reduces the time frame between tissue collection and application, thereby optimizing treatment outcomes for patients in urgent need of skin repairs.
In addition to its regenerative medicine products, RegenETP offers contract research services to partner organizations. These services leverage the company's expertise in tissue engineering and biomaterials to support research initiatives and advance the development of new therapeutics within the industry.
The company is actively expanding its portfolio of tissue regeneration products, focusing on innovative solutions that address various medical needs. These products are designed to enhance the regenerative capabilities of tissues beyond just skin, fostering advancements in stem cell therapy and related fields.